Is Ginkgo Bioworks Holdings, Inc. (DNA) Undervalued?
The traditional Graham Number cannot be calculated for Ginkgo Bioworks Holdings, Inc. (DNA) due to missing data. Consider using DCF or other valuation methods for a complete picture.
Analysis updated March 8, 2026
DNA Key Valuation Metrics
| Metric | Value | Signal |
|---|---|---|
| Current Price | $6.50 | — |
| Graham Number | N/A | — |
| P/E Ratio | N/A | Unprofitable |
| P/B Ratio | N/A | — |
| DCF Fair Value | N/A | — |
| Dividend Yield | N/A | N/A |
| 52-Week Range | $5.00 – $17.58 | Near 52-week low |
| Market Cap | N/A | Micro Cap |
| Sector | Healthcare | — |
How We Calculated DNA's Graham Number
The Graham Number, developed by Benjamin Graham (the father of value investing), estimates a stock's maximum fair price based on its earnings and book value.
Graham Number = √(22.5 × EPS × BVPS)
For Ginkgo Bioworks Holdings, Inc. (DNA):
- Earnings Per Share (EPS): N/A
- Book Value Per Share (BVPS): N/A
DNA Dividend Profile
Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend. This is common for growth-oriented companies that reinvest earnings back into the business to fund expansion, R&D, or acquisitions.
💡 For investors seeking income, check our Dividend Aristocrats for stocks with 25+ years of consecutive dividend increases.
DNA Value Score: 0/10
Our proprietary value score rates Ginkgo Bioworks Holdings, Inc. a 0 out of 10, placing it in the “Overvalued / Caution” category for value investors.
Score Components
Graham Number not available
P/E not available
P/B not available
DCF value not available
No dividend
Weak balance sheet metrics
Score methodology: How We Score Stocks
Stocks Similar to DNA
These Healthcare stocks have similar valuation profiles to Ginkgo Bioworks Holdings, Inc.:
Frequently Asked Questions About DNA
Is DNA undervalued right now?
Based on Graham Number analysis, DNA does not appear significantly undervalued as of March 8, 2026. The Graham Number of $N/A compared to the current price of $6.50 indicates a N/A% difference.
What is Ginkgo Bioworks Holdings, Inc.'s intrinsic value?
Using our DCF model, Ginkgo Bioworks Holdings, Inc.'s estimated intrinsic value is $N/A per share. The Graham Number suggests a fair value of $N/A.
What is the Graham Number for DNA?
The Graham Number for DNA is $N/A, calculated using EPS of $N/A and Book Value Per Share of $N/A. The formula is sqrt(22.5 x EPS x BVPS).
Does DNA pay a dividend?
No, Ginkgo Bioworks Holdings, Inc. does not currently pay a dividend. The company reinvests earnings into growth.
Is DNA a good buy right now?
Our value score rates DNA a 0/10. The stock is in the "Overvalued / Caution" category. However, this is analysis — not financial advice. Consider your own risk tolerance, portfolio allocation, and investment timeline before making any decisions.
Start Analyzing DNA Today
Ready to invest in Ginkgo Bioworks Holdings, Inc.? Open a free brokerage account and start trading DNA with $0 commissions.
We may earn a commission when you open an account through our links. This does not affect our analysis or ratings.
Learn More About Value Investing
Tools
- Graham Number Calculator — Calculate the Graham Number for any stock
- DCF Calculator — Run your own discounted cash flow analysis
- Stock Screener — Filter stocks by value metrics
Related Articles
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platf...
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial advice, a recommendation, or a solicitation to buy or sell any security. Past performance does not guarantee future results. Always do your own research and consult a licensed financial advisor before making investment decisions. Data sourced from Financial Modeling Prep API and may be delayed. Last updated: March 8, 2026.